Select Page ::

Neurologic Disorders Therapeutics Market Size, Trends, Growth, Scope, Overall Analysis and Forecast by 2027 – The Haitian-Caribbean News Network

Posted on November 30, 2020 by Danzig

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Neurologic Disorders Therapeutics Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Neurologic Disorders Therapeutics Market Overview

The Neurologic Disorders Therapeutics Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Neurologic Disorders Therapeutics market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Neurologic Disorders Therapeutics Market: Competitive Landscape

The Neurologic Disorders Therapeutics Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Neurologic Disorders Therapeutics Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Neurologic Disorders Therapeutics Market Segment by Type:

Neurologic Disorders Therapeutics Market Segment by Application:

Neurologic Disorders Therapeutics Market Regional overview:

In the report, experts analyze and forecast the Neurologic Disorders Therapeutics market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Neurologic Disorders Therapeutics Market Report:

Outlook analysis of the Neurologic Disorders Therapeutics market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Neurologic Disorders Therapeutics market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Study: Zika virus solution may lie in commonly used, tetracycline-based antibiotics – Homeland Preparedness News

Posted on November 30, 2020 by Danzig

Shutterstock

A preclinical study from the National Institutes of Health (NIH) suggests that tetracycline-based antibiotics like methacycline, or drugs designed to combat Alzheimers and inflammation, may slow infection and reduce neurological problems associated with the Zika virus.

This conclusion was based on use in mice after tests of more than 10,000 compounds. Researchers looked for drugs that would prevent Zika from reproducing by blocking the work of a protein known as NS2B-NS3 Zika virus protease. The protease releases proteins from RNA-injected cells that have been co-opted to produce more. By blocking these internal scissors, as study leader Dr. Rachel Abrams dubbed them, viruses like Zika can be counteracted.

Around the world, the Zika outbreak produced devastating, long-term neurological problems for many children and their families, said Dr. Avindra Nath, a senior investigator at the NIHs National Institute of Neurological Disorders and Stroke (NINDS) and a senior author of the study. Although the infections are down, the threat remains. We hope these promising results are a good first step to preparing the world for combating the next potential outbreak.

Zika is a primarily mosquito-spread virus that had its heyday in 2015 and 2016. It caused neurological disorders in adults and a developmental brain disorder in babies born from infected mothers. The virus prefers to attack stem cells in the brain.

In all, three drugs identified in this study may counteract the problems: methacycline, MK-591, or JNJ-404. Identifying these was achieved by feeding screening results into a computer and then using AI-based programs to assess what compounds would be good at blocking the protease activity. Tetracycline-based drugs are already approved by the U.S. Food and Drug Administration and are known to cross the placenta of pregnant women.

The antibiotics were not capable of fully counteracting the damage caused by Zika. Infected mice still had a lower weight than their control counterparts, whether treated with methacycline or not.

These results suggest that tetracycline-based antibiotics may at least be effective at preventing the neurological problems associated with Zika virus infections, Abrams said. Given that they are widely used, we hope that we can rapidly test their potential in clinical trials.

See the original post here:
Study: Zika virus solution may lie in commonly used, tetracycline-based antibiotics - Homeland Preparedness News

Diabetes, High Blood Pressure Raise Odds of COVID Harming Brain – HealthDay News

Posted on November 30, 2020 by Danzig

MONDAY, Nov. 30, 2020 (HealthDay News) -- COVID-19 patients with high blood pressure or diabetes may be more likely to develop critical neurological complications, including bleeding in the brain and stroke, according to an ongoing study.

University of Pennsylvania researchers studied COVID-19 patients who had a head CT scan or MRI within their health system between January and April 2020. In all, 81 of the 1,357 COVID-19 patients had a brain scan, usually because they had an altered mental state or speech and vision problems.

"COVID-19's effects extend far beyond the chest," said study lead author Dr. Colbey Freeman. He is chief resident in the department of radiology at Penn Medicine. "While complications in the brain are rare, they are an increasingly reported and potentially devastating consequence of COVID-19 infection," Freeman said.

Of the 81 patients, 18 (more than 20%) had critical or emergency brain issues, the scans revealed. At least half had histories of high blood pressure or type 2 diabetes. Three of the patients died in the hospital. Two-thirds of the patients with critical results were Black, according to the report.

"COVID-19 is associated with neurologic manifestations, and hypertension and type 2 diabetes mellitus are common in individuals who develop these manifestations," Freeman said in a news release from the Radiological Society of North America (RSNA). "These populations may be at higher risk for neurologic complications and should be monitored closely."

It is possible that inflammation is the reason for the observed neurological effects, the researchers said. Blood markers of inflammation were high in people with critical results.

"When your body is in an inflammatory state, it produces all these molecules called cytokines to help recruit the immune system to perform its function," Freeman explained. "Unfortunately, if cytokines are overproduced, the immune response actually starts doing damage."

The findings are scheduled for presentation at the RSNA's annual meeting, which is being held online Nov. 29 to Dec. 5. Research presented at meetings should be considered preliminary until published in a peer-reviewed journal.

The researchers are also investigating neurologic complications experienced by COVID-19 patients on a pump system that circulates and replenishes oxygen in the blood. They expect to report more findings as they become available.

"In addition, we have plans to initiate a larger prospective study evaluating delayed, long-term, and chronic neurologic manifestations that may not be known in this early period in the pandemic," Freeman said.

More information

The American Psychological Association has more information on COVID-19's impact on the brain.

SOURCE: Radiological Society of North America, news release, Nov. 18, 2020

Read the rest here:
Diabetes, High Blood Pressure Raise Odds of COVID Harming Brain - HealthDay News

Direct Imaging May Localize Seizure Onset Zone in Patients With Focal Epilepsy – Neurology Advisor

Posted on November 20, 2020 by Danzig

Direct imaging with high-density electroencephalography (EEG) may localize seizure onset zone prior to surgery in patients with focal epilepsy, according to study results published in Neurology.

Identifying the epileptogenic zone is crucial prior to surgical intervention for focal epilepsy and in recent years, EEG has become an important modality to guide surgical interventions. The objective of the current study was to assess the role of EEG recordings and source localization analyses in localizing seizure onset zone prior to surgical planning in patients with focal epilepsy.

The study included 39 adult patients (51.28% women; mean age, 17.87 years) with partial seizures who underwent pre-surgical evaluation with high-density long-term EEG monitoring at Mayo Clinic, Rochester, MN, between 2007 and 2017. Patients underwent either surgical resection or invasive intracranial EEG monitoring. Study researchers used a new method for directly imaging seizure sources and interictal spikes from high density EEGs, and confirmed it for seizure onset zone localization assessed with intracranial EEG findings and surgical resection volume.

There were a total of 138 seizures included in the study. The sub-lobar concordance rate between EEG seizure onset zone results and clinical findings was 94.87%. The difference was more significant in patients with greater than 1 interictal epileptic discharge cluster as ictal source imaging indicated a concordance rate of 87.5%.

The mean localization error, calculated as the average distance from the estimated source to the closest intracranial seizure onset zone electrode, was about 1.35 cm in patients with concordant results. For patients following successful surgery, the average distance from the estimated source to the boundary of the resected volume was 0.74 cm.

The interictal study included at least 10 hours of recordings for each patient. The concordance rate was 78.4% when study researchers used the dominant interictal epileptic discharge cluster for source imaging. The difference was more significant in patients with greater than 1 interictal epileptic discharge cluster as the interictal source imaging showed a concordance rate of 56.2%.

The study had several limitations, including limiting participants to patients with focal epilepsy, the use of high quality magnetic resonance imaging, and the use of high-density EEG.

The present study demonstrates the clinical applicability and merits of a noninvasive electrophysiological seizure imaging approach, which is currently missing in clinical routine, but may become an important component of the pre-surgical evaluation routine for epilepsy treatment, concluded the study researchers.

Reference

Ye S, Yang L, Lu Y, et al. Contribution of ictal source imaging for localizing seizure onset zone in patients with focal epilepsy patients. Neurology. Published online October 23, 2020. doi:10.1212/WNL.0000000000011109

Read the original post:
Direct Imaging May Localize Seizure Onset Zone in Patients With Focal Epilepsy - Neurology Advisor

Society of Vascular and Interventional Neurology Releases Study on Paradigm Shifts in Medical Care During COVID-19 Pandemic – Southernminn.com

Posted on November 20, 2020 by Danzig

MINNEAPOLIS, Nov. 19, 2020 /PRNewswire/ -- The Society of Vascular and Interventional Neurology(SVIN)colleagues andDr. James Siegleridentify that it should come as no surprise that the COVID-19 pandemic and its many "waves" has led to significant paradigm shifts in medical care--from triage all the way to treatment, and SVIN and Dr. Sieglerare releasing a study on Paradigm Shifts in Medical Care During COVID-19Pandemic. Many reports have indicated that patients are avoiding healthcare institutions to prevent contact with COVID-19 patients and healthcare professionals.Falling rates have been observed across a range of acute and critical conditions including myocardial infarction, stroke, and various cancers.The long-term consequences of healthcare avoidance remain unknown but will become clear in the coming months and years.

Using a novel lens to explore these indirect consequences of the COVID-19 pandemic,Dr.Sieglerand colleagues from the Society of Vascular andInterventionalNeurology undertook amulticenterobservational study to evaluate the timeline of critical care that is provided to patients with acute ischemic stroke. These investigators pooled prospectively maintained data from 14 Comprehensive Stroke Centers (CSCs) in nine U.S. states between January 2019 and July 2020.Together, these nine states accounted for nearly half of all COVID-19 cases in the U.S. and more than one-third of all COVID-19-associatedmortalities.(If any indirect effect of the pandemic were to influence the care of stroke patients, it would involve these high-risk geographical regions.) The objective of this investigation was to determine if patients were receiving standard-of-carereperfusiontherapies (e.g., intravenousthrombolysisand/orthrombectomy) with the same expediency during the COVID-19 period as they were in the months prior. Using the AHA Target: Stroke campaign goal of a 60-minute door-to-needle time for intravenousthrombolysisas a primary outcome, the authors found that patients admitted to these hospitals during the COVID-19 pandemic were at a 45% lower odds of being treated in that 60-minute time window (adjusted OR 0.55, 95%CI 0.35-0.85).

The investigators were also able to track the times from patient arrival to firstneuroimagingtothrombolysisbolus. It appears that the principal mediator of the delay inthrombolysiswas the delay in time from head imaging to bolus (median delay of sevenminutes across all sites).Despite the increased need for personal protective equipment, contact precautions, and other barriers between patients and providers, there appeared to be no delay in time from arrival to firstneuroimaging.Furthermore, the delay in care appeared to persist throughout the months of June and July as the second wave of the pandemic spread across the southeastern and western United States.While the overall delay tothrombolysiswas minimal (median delay of only fourminutes), this delay was observed inCSCs, which are known to have faster throughput and treatment times when compared to other healthcare institutions.It is possible that this delay may be magnified in community hospitals, and these findings warrant exploration in non-CSC institutions.

Although there was a mild but significant delay in door-to-needle times during the COVID-19 pandemic, there appeared to be no significant delay in door-to-groin puncture times for patients who underwentendovascularrecanalizationduring COVID-19. This may reflect the careful planning and anticipation of COVID-19 patient care by leaders within the Society of Vascular andInterventionalNeurology, as their consensus guidelines had been published early during the pandemic.

Altogether, these findings suggest large scale gaps in acute medical care for a common neurological problem that affects almost 1 million Americans perannum. It is important for healthcare institutions to appraise their local paradigms in acute stroke care to determine if similar gaps exist, and what steps they can take to reduce delays in care during a global crisis.

About SVIN

The Society of Vascular andInterventionalNeurologyachieves the highest level ofpatient care through collaboration in scientific research and education.The Society provides opportunities to connect leaders in the field and provides a platform for dialogue and creation of practicestandards.Our mission is to advance vascular andinterventionalneurologyto improve clinical outcomes of stroke and cerebrovascular disorders.

For further information about SVIN, visitwww.svin.orgor find us on Facebook, Twitter, orLinkedIn.Media Contact: Jennifer Potter-Vig, PhD |info@svin.org|952-646-2045

Related Images

dr-jim-siegler.jpgDr. Jim SieglerSpeaking on behalf of the Society of Vascular and Interventional Neurology (SVIN) COVID-19 Registry & Task Force at the SVIN Annual Meeting on Thursday, November 19, 2020.

Neurological Symptoms Mixed with COVID-19 May Mean Double the Worse Outcomes – DocWire News

Posted on November 13, 2020 by Danzig

Its been documented that patients with preexisting conditions may have greater risks when it comes to COVID-19. Now, according to research, patients with neurological symptoms and COVID-19 may be at risk for not only more severe COVID-19 symptomsbut exacerbated neurological symptoms as well.

The authors of the study queried the MEDLINE and medRxiv databases for relevant studies that reported on patients with preexisting neurological disorders and COVID-19 that reported the severity of the latter and/or changes in symptoms of the former. Severe COVID-19 was defined as having severe/critical pneumonia or admission to the intensive care unit.

Of 1,702 total studies identified (866 from MEDLINE, 836 from medRxiv), 26 studies encompassing 2,278 total patients were included in the final analysis. The disorders represented in the studies included cerebrovascular disease, Parkinsons disease, multiple sclerosis and related disorders, aquaporin-4 (AQP-4)-positive neuromyelitis optica spectrum disorder (NMOSD), dementia and cognitive disorder, epilepsy, spinal cord injury, systemic atrophy, myelopathy, intracranial mass, and unspecified disorders.

Not every study discussed both outcomes (the exacerbation of neurological symptoms and COVID-19 severity), so patients were stratified by those with preexisting neurological disorders and COVID-19 for where exacerbation of neurological symptoms was available (n=232) and where the severe COVID-19 course was available (n=2,618).

Among the patients whose neurological symptoms exacerbation was reported, 74 (31.9%) presented exacerbated preexisting neurological symptoms. This was observed in more than half of the patients with dementia (n=55/92; 59.5%) and Parkinsons disease (n=10/17; 58.8%).

Among the patients whose COVID-19 severity course was reported, 478 (22%) presented worsening COVID-19 severity. This was observed in about one-fifth of patients with cerebrovascular disease (n=86/445; 19.3%) and dementia (n=70/316; 22.2%) and two in five patients with multiple sclerosis (n=28/71; 39.4%); it was also seen in patients Parkinsons disease (25/214; 11.7%), epilepsy (10/98; 10.2%), spinal cord injury (5/7; 71.1%), and unspecified neurological disorders (254/1011; 25%).

The study was published in Clinical Neurology and Neurosurgery.

Clinicians should be aware of the risks of an exacerbation of neurological symptoms and an increase in COVID-19 severity in patients with preexisting neurological diseases, and should focus on the prevention and early care of COVID-19, the researchers concluded.

Read this article:
Neurological Symptoms Mixed with COVID-19 May Mean Double the Worse Outcomes - DocWire News

New NIH BRAIN Initiative awards move toward solving brain disorders – National Institutes of Health

Posted on November 20, 2020 by Danzig

News Release

Thursday, November 19, 2020

Researchers using recently developed tools to gain new insights into brain function.

The National Institutes of Health will fund more than 175 grants, totaling nearly $500 million, through the NIHs Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, part of a large effort among federal and non-federal partners to use knowledge about how the brain works to develop more effective therapies for neurological disorders.

Recent discoveries and new technologies supported by the BRAIN Initiative provide a solid foundation for the next phase of the program, which will focus on large transformative projects and lay the foundation for novel interventions for human brain disorders, said John Ngai, Ph.D., director of the NIH BRAIN Initiative. We are moving closer to a complete list of all of the components in the brain and learning how those parts work together. That knowledge will enable us to develop better treatments for neurologic and neuropsychiatric diseases.

The researchers represent a variety of scientific disciplines from chemistry to engineering to psychology and more.

The new awards include efforts to use deep brain stimulation to enhance sleep in people with Parkinsons disease; explore the neural circuits behind pain; employ ultrasound technology to precisely deliver drugs to the brain; and help people with acute spinal cord injury recover movements and bladder control.

Scientists are also making significant advances in human brain imaging by developing a new type of MRI scanner to watch the brain in action as someone moves; generating ultra-high resolution images of brain chemistry using new PET technology; and using ultrasound to noninvasively map brain electrical activity.

Some grants support integrated research on neuroethical implications of BRAIN-funded neuroscience projects, including issues concerning certain types of neurosurgery and ethical challenges of using mobile neuroimaging technology in field studies.

Meanwhile, others will take a unique approach to studying the brain by developing a range of innovative model systems, beyond traditional fruit flies and rodents. For example, they will study the circuits behind the way an octopus sees and makes decisions; how moths detect harmful stimuli; and the brain connections bats use to navigate in the dark. These studies will provide insights into ways that brain circuitry can affect human behavior.

The BRAIN Initiative started in 2013 as a large-scale effort to accelerate neuroscience research by providing researchers with tools to study and treat human brain disorders. The NIH BRAIN Initiative has focused on brain circuit structure and function as well as the development of technologies to manipulate connections. To date, more than 900 awards totaling approximately $1.8 billion have been supported by the NIH BRAIN Initiative, which is collaboratively managed by 10 institutes.

A number of BRAIN Initiative-supported research findings have been published over the past year including identification of neurons that help rats envision future scenarios; the discovery of specific cells activated by general anesthesia and that may be potential targets for chronic pain treatments; advances in imaging technology that can measure brain activity up to 3,000 times per second in animals; examining nonverbal behavior in people with severe depression who receive deep brain stimulation; watching as odor-sensing cells within the nose react to complex smells; finding brain cells that can initiate torpor, a state of inactivity similar to hibernation; and a new device that may allow real-time control of prosthetic limbs.

For more information, please visit:https://braininitiative.nih.gov/

The NIH BRAIN Initiative is managed by 10 institutes whose missions and current research portfolios complement the goals of the BRAIN Initiative: National Center for Complementary and Integrative Health, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and other Communication Disorders, National Institute of Mental Health, and National Institute of Neurological Disorders and Stroke.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Continued here:
New NIH BRAIN Initiative awards move toward solving brain disorders - National Institutes of Health

Minimally Invasive Neurosurgical Systems Industry to 2030 Rising cases of neurological disorders and growing demand for efficient minimally invasive…

Posted on December 8, 2021 by Danzig

The global minimally invasive neurosurgical systems market size was US$ 467 million in 2021. The global minimally invasive neurosurgical systems market is forecast to grow to US$1,162 million by 2030, growing at a compound annual growth rate (CAGR) of 10.5% during the forecast period from 2022 to 2030.

Request for A Sample Report: https://reportocean.com/industry-verticals/sample-request?report_id=Pol550

The use of minimally invasive neurosurgical systems can be helpful in many ways. It helps surgeons have better visualization than the traditional methods. Moreover, it allows a small incision of the skull during the surgical process.

Factors Influencing

Geographic Overview

North America is forecast to dominate the global minimally invasive neurosurgery system market due to the rapidly rising cases of neurological disorders. Moreover, the increasing penetration of advanced technology and high healthcare expenditure will benefit the global market.

In addition, the rapidly developing healthcare sector and increasing awareness about minimally invasive neurosurgical treatments among the population are forecast to benefit the regional market.

COVID-19 Impact Analysis

Due to the COVID-19 pandemic, the global minimally invasive neurosurgical systems market witnessed an abrupt decline. The authorities and healthcare bodies all around the world were concentrating on curbing the effect of the virus and saving the lives of the people. As a result of this, neurological surgeries were either postponed or canceled for a short period of time. Moreover, patients also stopped visiting hospitals and clinics to prevent themselves from the effect of this deadly virus. Thus, the global minimally invasive neurosurgical systems market witnessed a significant decline.

The global minimally invasive neurosurgical systems market also slowed down due to the unavailability of raw materials, which created various challenges for the market players.

Competitors in the Market

Market Segmentation

The global minimally invasive neurosurgical systems market is segmented on the basis of Product, Surgery Type, and Region.

Insight by Product Type

Insight by Surgery Type

Insight by Region

Factors Influencing

Geographic Overview

In addition, the rapidly developing healthcare sector and increasing awareness about minimally invasive neurosurgical treatments among the population are forecast to benefit the regional market.

COVID-19 Impact Analysis

The global minimally invasive neurosurgical systems market also slowed down due to the unavailability of raw materials, which created various challenges for the market players.

Competitors in the Market

Market Segmentation

The global minimally invasive neurosurgical systems market is segmented on the basis of Product, Surgery Type, and Region.

Insight by Product Type

Insight by Surgery Type

Insight by Region

Download Free Sample Copy of Minimally Invasive Neurosurgical Systems Market@ https://reportocean.com/industry-verticals/sample-request?report_id=Pol550

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Report Ocean

Name: Nishi Sharma

Email: sales@reportocean.com

Address: 500 N Michigan Ave, Suite 600, Chicago, IIIinois 60611 UNITED STATES

Tel: +1 888 212 3539 (US TOLL FREE)

Website: https://www.reportocean.com/

Original post:
Minimally Invasive Neurosurgical Systems Industry to 2030 Rising cases of neurological disorders and growing demand for efficient minimally invasive...

Impact Of Covid-19 on Neurology Emr Software Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 – PRnews Leader

Posted on October 31, 2020 by Danzig

Overview for Neurology Emr Software Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

The global Neurology Emr Software market focuses on encompassing major statistical evidence for the Neurology Emr Software industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Neurology Emr Software study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Neurology Emr Software industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Neurology Emr Software market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Neurology Emr Software report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Neurology Emr Software market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Neurology Emr Software Market report @ https://hongchunresearch.com/request-a-sample/53014

Key players in the global Neurology Emr Software market covered in Chapter 4:, Athenahealth, Kareo, Nextgen, Brainlab, Bizmatics, Practice Fusion, Allscripts, NueMD, Advanced Data Systems, Epic, Greenway Health, Healthfusion

In Chapter 11 and 13.3, on the basis of types, the Neurology Emr Software market from 2015 to 2026 is primarily split into:, Advanced Neurology EMR Software, Other

In Chapter 12 and 13.4, on the basis of applications, the Neurology Emr Software market from 2015 to 2026 covers:, Hospitals, College & Research Institutes, Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

The Neurology Emr Software market study further highlights the segmentation of the Neurology Emr Software industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Neurology Emr Software report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Neurology Emr Software market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Neurology Emr Software market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Neurology Emr Software industry as it explores the competitive nature of the market complete with a regional analysis.

Check [emailprotected] https://hongchunresearch.com/check-discount/53014

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Neurology Emr Software Market

Chapter Four: Players Profiles

Chapter Five: Global Neurology Emr Software Market Analysis by Regions

Chapter Six: North America Neurology Emr Software Market Analysis by Countries

Chapter Seven: Europe Neurology Emr Software Market Analysis by Countries

Chapter Eight: Asia-Pacific Neurology Emr Software Market Analysis by Countries

Chapter Nine: Middle East and Africa Neurology Emr Software Market Analysis by Countries

Chapter Ten: South America Neurology Emr Software Market Analysis by Countries

Chapter Eleven: Global Neurology Emr Software Market Segment by Types

Chapter Twelve: Global Neurology Emr Software Market Segment by Applications 12.1 Global Neurology Emr Software Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Neurology Emr Software Sales and Market Share by Applications (2015-2020) 12.1.2 Global Neurology Emr Software Revenue and Market Share by Applications (2015-2020) 12.2 Hospitals Sales, Revenue and Growth Rate (2015-2020) 12.3 College & Research Institutes Sales, Revenue and Growth Rate (2015-2020) 12.4 Other Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Neurology Emr Software Market Forecast by Regions (2020-2026) continued

List of tablesList of Tables and Figures Table Global Neurology Emr Software Market Size Growth Rate by Type (2020-2026) Figure Global Neurology Emr Software Market Share by Type in 2019 & 2026 Figure Advanced Neurology EMR Software Features Figure Other Features Table Global Neurology Emr Software Market Size Growth by Application (2020-2026) Figure Global Neurology Emr Software Market Share by Application in 2019 & 2026 Figure Hospitals Description Figure College & Research Institutes Description Figure Other Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Neurology Emr Software Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Neurology Emr Software Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Neurology Emr Software Figure Production Process of Neurology Emr Software Figure Manufacturing Cost Structure of Neurology Emr Software Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table Athenahealth Profile Table Athenahealth Production, Value, Price, Gross Margin 2015-2020 Table Kareo Profile Table Kareo Production, Value, Price, Gross Margin 2015-2020 Table Nextgen Profile Table Nextgen Production, Value, Price, Gross Margin 2015-2020 Table Brainlab Profile Table Brainlab Production, Value, Price, Gross Margin 2015-2020 Table Bizmatics Profile Table Bizmatics Production, Value, Price, Gross Margin 2015-2020 Table Practice Fusion Profile Table Practice Fusion Production, Value, Price, Gross Margin 2015-2020 Table Allscripts Profile Table Allscripts Production, Value, Price, Gross Margin 2015-2020 Table NueMD Profile Table NueMD Production, Value, Price, Gross Margin 2015-2020 Table Advanced Data Systems Profile Table Advanced Data Systems Production, Value, Price, Gross Margin 2015-2020 Table Epic Profile Table Epic Production, Value, Price, Gross Margin 2015-2020 Table Greenway Health Profile Table Greenway Health Production, Value, Price, Gross Margin 2015-2020 Table Healthfusion Profile Table Healthfusion Production, Value, Price, Gross Margin 2015-2020 Figure Global Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Global Neurology Emr Software Revenue ($) and Growth (2015-2020) Table Global Neurology Emr Software Sales by Regions (2015-2020) Table Global Neurology Emr Software Sales Market Share by Regions (2015-2020) Table Global Neurology Emr Software Revenue ($) by Regions (2015-2020) Table Global Neurology Emr Software Revenue Market Share by Regions (2015-2020) Table Global Neurology Emr Software Revenue Market Share by Regions in 2015 Table Global Neurology Emr Software Revenue Market Share by Regions in 2019 Figure North America Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Europe Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Asia-Pacific Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Middle East and Africa Neurology Emr Software Sales and Growth Rate (2015-2020) Figure South America Neurology Emr Software Sales and Growth Rate (2015-2020) Figure North America Neurology Emr Software Revenue ($) and Growth (2015-2020) Table North America Neurology Emr Software Sales by Countries (2015-2020) Table North America Neurology Emr Software Sales Market Share by Countries (2015-2020) Figure North America Neurology Emr Software Sales Market Share by Countries in 2015 Figure North America Neurology Emr Software Sales Market Share by Countries in 2019 Table North America Neurology Emr Software Revenue ($) by Countries (2015-2020) Table North America Neurology Emr Software Revenue Market Share by Countries (2015-2020) Figure North America Neurology Emr Software Revenue Market Share by Countries in 2015 Figure North America Neurology Emr Software Revenue Market Share by Countries in 2019 Figure United States Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Canada Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Mexico Neurology Emr Software Sales and Growth (2015-2020) Figure Europe Neurology Emr Software Revenue ($) Growth (2015-2020) Table Europe Neurology Emr Software Sales by Countries (2015-2020) Table Europe Neurology Emr Software Sales Market Share by Countries (2015-2020) Figure Europe Neurology Emr Software Sales Market Share by Countries in 2015 Figure Europe Neurology Emr Software Sales Market Share by Countries in 2019 Table Europe Neurology Emr Software Revenue ($) by Countries (2015-2020) Table Europe Neurology Emr Software Revenue Market Share by Countries (2015-2020) Figure Europe Neurology Emr Software Revenue Market Share by Countries in 2015 Figure Europe Neurology Emr Software Revenue Market Share by Countries in 2019 Figure Germany Neurology Emr Software Sales and Growth Rate (2015-2020) Figure UK Neurology Emr Software Sales and Growth Rate (2015-2020) Figure France Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Italy Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Spain Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Russia Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Asia-Pacific Neurology Emr Software Revenue ($) and Growth (2015-2020) Table Asia-Pacific Neurology Emr Software Sales by Countries (2015-2020) Table Asia-Pacific Neurology Emr Software Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Neurology Emr Software Sales Market Share by Countries in 2015 Figure Asia-Pacific Neurology Emr Software Sales Market Share by Countries in 2019 Table Asia-Pacific Neurology Emr Software Revenue ($) by Countries (2015-2020) Table Asia-Pacific Neurology Emr Software Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Neurology Emr Software Revenue Market Share by Countries in 2015 Figure Asia-Pacific Neurology Emr Software Revenue Market Share by Countries in 2019 Figure China Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Japan Neurology Emr Software Sales and Growth Rate (2015-2020) Figure South Korea Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Australia Neurology Emr Software Sales and Growth Rate (2015-2020) Figure India Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Southeast Asia Neurology Emr Software Sales and Growth Rate (2015-2020) Figure Middle East and Africa Neurology Emr Software Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Neurology Emr Software :

HongChun Research, Neurology Emr Software , Neurology Emr Software market, Neurology Emr Software industry, Neurology Emr Software market size, Neurology Emr Software market share, Neurology Emr Software market Forecast, Neurology Emr Software market Outlook, Neurology Emr Software market projection, Neurology Emr Software market analysis, Neurology Emr Software market SWOT Analysis, Neurology Emr Software market insights

Read the rest here:
Impact Of Covid-19 on Neurology Emr Software Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - PRnews Leader

COVID-19 Update: Global Neurology EMR Software Market is Expected to Grow at a Healthy CAGR with Top players: NueMD, Greenway Health, AdvancedMD,…

Posted on October 31, 2020 by Danzig

Neurology EMR Software Marketreport analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios. The report covers the present scenario and the growth prospects of the global Neurology EMR Softwaremarket for 2020-2025.

The Neurology EMR SoftwareMarket Report further describes detailed information about tactics and strategies used by leading key companies in the Neurology EMR Softwareindustry. It also gives an extensive study of different market segments and regions.

Request For Exclusive Sample PDF along with few company profileshttps://inforgrowth.com/sample-request/6524466/neurology-emr-software-market

The Top players are

Market Segmentation:

By Product Type:

On the basis of the end users/applications,

HALLOWEEN OFFER: Get up-to 30% Extra Discount for this Exclusive Gene Synthesis Service Market Report, https://inforgrowth.com/discount/6524466/neurology-emr-software-market

Impact of COVID-19:

Neurology EMR Software Market report analyses the impact of Coronavirus (COVID-19) on the Neurology EMR Software industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Neurology EMR Software market in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6524466/neurology-emr-software-market

Reasons to Get this Report:

Study on Table of Contents:

ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/6524466/neurology-emr-software-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website:

Read the original here:
COVID-19 Update: Global Neurology EMR Software Market is Expected to Grow at a Healthy CAGR with Top players: NueMD, Greenway Health, AdvancedMD,...

Overweight/Obesity in Young Adulthood Linked to Increased Risk of MS – Neurology Advisor

Posted on February 15, 2021 by Danzig

Overweight/obese levels of BMI at age 20, paired with history of infectious mononucleosis (IM) or high Epstein-Barr nuclear antigen 1 (EBNA-1) antibody levels, synergize in elevating the risk of multiple sclerosis (MS), and the effect strengthens with increasing antibody levels, according to study results published in Neurology: Neuroimmunology & Neuroinflammation. Results also indicated significant 3-way additive interactions between DRB1*15:01 allele, BMI at age 20 years, and each aspect of Epstein Barr virus (EBV) infection.

The study researchers sought to find out whether these MS risk factors had an additive interaction for the inflammatory disease, and to analyze 3-way interactions between BMI at age 20, EBV infection, and the human leukocyte antigen (HLA)-DRB1* 15:01 allele.

They used data from the Epidemiological Investigation of Multiple Sclerosis (EIMS) and Genes and Environment in Multiple Sclerosis (GEMS) studies, 2 Swedish population-based case-control studies on environmental and genetic risk factors for MS. In the former, newly diagnosed cases of MS were recruited from neurology clinics and matched with 2 randomly selected controls from the countrys national population register, frequency matched in 5-year age strata, sex, and residential area. GEMS presented prevalent cases of MS from the Swedish National MS Registry, each of whom was matched with 1 control in the same way as in EIMS.

The study researchers also included controls from the Epidemiological Investigation of Rheumatoid Arthritis, which was designed in the same manner and with a similar study population as EIMS. Participants provided blood samples for the genotyping and self-reported contraction of IM, body height, and weight.

The combination of two risk factors, overweight/obesity at age 20 years and a history of IM, synergistically increased the risk of MS 5-fold. In contrast, nonoverweight subjects with IM history had a 90% increased risk of MS and those with overweight/obesity at age 20 years (BMI I 25 kg/m2) without IM history had a 40% increased MS risk.

BMI at age 20 years and high EBNA-1 antibody levels, even without history of IM, had a similar interaction that increased with elevated EBNA-1 antibody levels.

2-way interactions were present between DRB1*15:01 and overweight/obesity at age 20 years, between DRB1*15:01 and each aspect of EBV infection, and between overweight/obesity at age 20 years and each aspect of EBV infection. DRB1*15:01, BMI at age 20 years, and each aspect of EBV infection (IM history and high EBNA-1 antibody levels, respectively) had significant 3-way interactions.

These findings held significant for both EIMS and GEMS when investigators restricted the analysis to subjects with complete data on HLA alleles and EBNA-1 antibody levels.

Limitations of the study included selection bias and recall bias in the studies and risk of misclassification when dichotomizing subjects into those with and without self-reported IM history.

The study researchers concluded, The obese state both induces a chronic immune-mediated inflammation and affects the cellular immune response to infections, which may contribute to explain our findings. They added that their data reinforce the importance of intervention efforts against childhood and adolescent obesity to reduce MS incidence.

Disclosure: Several authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Hedstrm AK, Brenner N, Butt J, et al. Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology. Neurol Neuroimmunol Neuroinflamm. Published online December 15, 2020. doi:10.1212/NXI.0000000000000912

Read the rest here:
Overweight/Obesity in Young Adulthood Linked to Increased Risk of MS - Neurology Advisor

20 Years Later, The Pressures and Opportunities Facing… : Neurology Today – LWW Journals

Posted on November 7, 2021 by Danzig

Article In Brief

The loss of protected time for research and a focus on clinical revenue and relative value units has changed the traditional balance of academic neurology from the traditional triad of research, teaching, and clinical practice. But some of the changes in the last 20 years are for the better, academic neurology chairs told Neurology Today.

With great advances comes greater pressure to deliver clinical care to patients.

Twenty-one years into the 21st century, neurology chairs across the United States say that academic medicine has seen vast changesmany of them exciting, some not so much.

On the plus side, new discoveries and treatments offer neurologists new tools and subspecialties to treat more patients.

When I was a student and resident, I would hear people say, Neurology is diagnose and adios, said Matthew Rizzo, MD, FAAN, professor and chair of the department of neurological sciences at the University of Nebraska. It's not that at all now. So many treatments are available for the acute and chronic diseases we treat. And there are more and more people who seek neurologic care. What I see is opportunity upon opportunity.

At the same time, he and four other chairs who spoke to Neurology Today agreed, demands on academic neurologists to spend more time treating patients and less time on research and teaching have led to increased stress and, for some, burnout.

The emphasis on high throughput has definitely hurt academic neurology, said Clifton Gooch, MD, FAAN, professor and chair of neurology at the University of South Florida's (USF) Morsani College of Medicine. Neurology has more complicated patients than most other areas of medicine to begin with, and the most challenging patients from within this group are referred to academic neurology departments. So when some health systems say, We want you to spend 30 minutes on a new patient with severe Alzheimer's disease and 15 minutes to follow up a complex Parkinson's disease patient, you simply can't provide adequate care, and that puts you under tremendous stress. Department leadership is critical to mitigate demands such as these on faculty, but it can be challenging.

On balance, though, all five chairs said the positives in today's academic neurology far outweigh the negatives.

I finished my fellowship in 1987, when there was more protected time for research and teaching, said Kathleen M. Shannon, MD, FAAN, FANA, professor and chair of neurology at the University of Wisconsin School of Medicine and Public Health. Since then, she said, The pressure for patient care has really, really gone up. That has led to a lot of burnout issues. But don't get me wrong. Academic neurology is a wonderful place. It still attracts the very best people, who are 100 percent committed to taking care of their patients and making their lives better. I really love what I do. It's just hard to know the struggles that my folks are facing.

To help neurologists in every career path better handle the challenges of practicing in an academic setting, the AAN established an Academic Neurology Initiative under its past president, Ralph L. Sacco, MD, FAAN, FAHA, professor and chair of neurology at the University of Miami Leonard Miller School of Medicine.

Many people went into academic medicine to do research and teaching, but the clinical mission is growing more rapidly, Dr. Sacco said. The revenue for academic health systems is much more dependent now on clinical revenues. The AAN felt strongly there was more help needed for neurologists in academic medical centers to deal with the new realities.

Back in the day, Dr. Rizzo said, Neurology departments were basically fiefdoms. Department chairs had a lot of power and leverage over the way money got spent, how the clinic was organized. What I've seen over the course of my career is the corporatization of medicine. You have C-suites and CFOs and CEOs. When I started out, all we had were doctors, nurses, ward clerks, and patients. It was pretty simple.

Dr. Gooch, who in 2017 published a survey of academic neurology departments, described the last couple of decades of the 20th century as a fiscal golden age for neurologists and other physicians.

There was a lot more money in medicine at that time, he said. The baby boomers were younger and healthier, working and paying into the health insurance system while consuming fewer services and clinical reimbursement was good. States provided a much greater portion of most medical school budgets. There was funded time to teach and do research, including small exploratory and/or descriptive clinical research projects. The clinical productivity metric of RVUs [relative value units] were first introduced in 1989, and were not yet an unyielding standard of performance .

Changes accelerated with the advent of managed care, Dr. Gooch said. As we approached the year 2000, the baby boomers started retiring and began consuming health care rather than working and paying into the system. This and other factors, including the development of more expensive technologies and treatments, contributed to rising health care costs, causing Medicare and businesses to look for ways to rein in expenses. Consequently, managed care was born, with a major focus on cutting reimbursement for clinical services, he said. At the same time, state support fell. When I became chair here at USF in 2008, 40 percent of the medical school's budget was from the state. Now it's below 10 percent and continues to fall.

Steven Galetta, MD, FAAN, professor and chair of neurology at NYU Grossman School of Medicine, said that back in the 1990s, Most of us were doing general neurology. As the decade progressed, subspecialty fellowships emerged, particularly for stroke and neurocritical care. We started off with no headache medicine specialists. Now we have six.

As more medicines became available for headaches, multiple sclerosis, stroke, and other disorders, the demand for neurological care became tremendous, Dr. Galetta said. As NYU has taken over smaller health systems in nearby Brooklyn and Long island, he said, We went from seeing 7,000 outpatients in 2012 to nearly 100,000 this year. We've hired over a hundred neurologists in those years.

Even as total US spending on health care has grown vastly in the 21st century, reaching $3.8 trillion in 2019amounting to 17.7 percent of the nation's gross domestic productthe portion going to academic neurologists has hardly kept pace.

The pie has gotten bigger, Dr. Gooch said, but pharma is consuming a much bigger percentage of the pie, and the insurance industry is taking its cut too.

Another irony in the evolution of academic medicine is that while the total amount of research money available from the National Institutes of Health (NIH) has grown, getting an NIH grant for a clinical trial has become increasingly difficult.

While the NIH is the major source of funding for critical basic biomedical researchmouse models of disease, cell cultures, etc., only a very small percentage of the NIH budget is dedicated to human clinical trials, which are very expensive, Dr. Gooch said.

In the past, much of this work, especially exploratory therapeutic studies in humans, was funded by excess clinical revenues, which dried up in the late 90s, Dr. Gooch said. This means a lot of this very important early phase clinical research has been pared back. At the same time, NIH-funded basic research has become the coin of the realm in most academic centers, with broad influence on metrics such as the US News medical school rankings.

As with so many other workers in the 21st century, academic neurologists are now gauged by measures of their productivity.

In the old days, you got a salary and you did your workclinical, teaching, research, and administration, Dr. Sacco said. Now each component is measured. And the measure of clinical productivity is by RVUs. When a clinician sees a patient, or reads an EEG or EMG, they generate a certain amount of RVUs. It's become more metrics-driven. If you're not making your clinical RVUs, your salary could be reduced or you might have to do more clinical time to support your salary.

Despite all the pressures, Dr. Rizzo said, It's crazy to be negative. We have so much opportunity. More and more people need neurological care.

That optimistic view was echoed by Frances E. Jensen, MD, FAAN professor and chair of neurology at the University of Pennsylvania's Perelman School of Medicine.

Academic neurology is in an incredibly dynamic state right now, she said. I am unbelievably excited. I pinch myself every day that I'm actually in the field I'm in. We are moving ahead at a pace that is unprecedented for our field. Twenty-five years ago, neurology was more of a watch and wait and document field. What's happening now, because so many treatments are translating to direct patient care, is we're seeing new opportunities and career paths emerge. We're seeing interactions with industry. There are people looking at population-based studies, public health, operations, safety, and quality.

That's not to say it's all gumdrops and unicorns. Yes, of course, my faculty have to mind their RVUs, Dr. Jensen said. But we also focus on having them participate at the top of their licensure. If you continually ask people to work below their licensure, it becomes demoralizing for them, and you are not tapping their potential for program growth. So we work hard to think about how to use physician assistants and advanced practice nurses. The documentation required in electronic medical records is not going to go away. The question is: How do we automate or find other professionals to handle some of it? We have to be adaptive.

Dr. Gooch said he sees hope for reducing the pressure on academic neurologists to see ever more patients in less time is by moving away from a fee-for-service model.

The movement to population health management changes the whole paradigm, he said. It means each health system gets a set amount of money each year to treat a defined population in their area. So the game becomes here's the money, this is it, use it wisely. Now you want to do fewer expensive procedures. You want to invest in internists, neurologists, and family practitioners to keep your population healthy so that they don't need surgery or emergency medical care. In this model, which is more logical, cost effective, and most importantly, better for the patient, the value of clinical neurology will soar, along with the other cognitive specialties.

The move to population health management is already well underway and is a major strategy of the Affordable Care Act in the form of Accountable Care Organizations ( ACOs). Existing large health maintenance organizationtype health systems are best positioned to transition to the ACO model, and many academic medical centers are actively expanding to enter this space.

For all the changes that have affected academic neurology in the past 20 years and will continue to do so, Dr. Rizzo said, What hasn't changed is the neurologist's diligence, aptitude, and appetite for solving really hard clinical problems and digging into the science to find cures. Neurologists remain a very special group of people.

Dr. Sacco said he, too, remains optimistic. With every challenge comes a new opportunity, he said. We will remain resilient and work collectively together to chart a new course forward.

None of the sources quoted in this stories had conflicts of interest to report.

Read the rest here:
20 Years Later, The Pressures and Opportunities Facing... : Neurology Today - LWW Journals

Hutch Clinic welcomes new physicians in Neurology and OB/GYN – The Hutchinson News

Posted on February 6, 2021 by Danzig

By The News staff| The Hutchinson News

Hutchinson Clinic announced the addition of two doctors to its roster of physicians Drs. Rizwan Hassan and Jessica Poteet.

Dr. Hassan comes to Hutchinson from Wichita, where he has more than 40 years of experience diagnosing and treating neurological conditions ranging from epilepsy, Parkinsons, dementia, multiple sclerosis, and stroke.

Most recently, he worked with the Neurology Associates of Kansas to conduct neurological testing and procedures.

In neurology, a specialty that affects all systems of the body, Dr. Hassan approaches patient care with a long-term relationship in mind, acting with compassion and collaborating with other specialists to determine his patients best care path forward.

Dr. Poteet, a graduate of Oklahoma State University College of Osteopathic Medicine, comes to Hutchinson from Utica Park Clinic of Owasso, Oklahoma. She also served as Chief of Surgery for Bailey Medical Center and previously as Chief Resident for St. Anthony Hospital.

Dr. Poteet aims to be a health partner to the women she serves.

She takes a creative and personalized approach to care, assessing the wants and needs of her patients to find solutions that they are comfortable with and to support them during big life moments.

Hutchinson Clinic is expanding access to high-quality care in 2021 with the addition of these two new physicians to our leading clinical team, said Mike Heck, CEO of Hutchinson Clinic.

Dr. Rizwan Hassan will offer new expertise to our patients and play a vital role in building our neurology services," he said. "Our OB/GYN team continues to grow, serving mothers, women, and families in our community, with the addition of Dr. Jessica Poteet. They are both excellent providers who share in our mission and passion for serving the community.

Both are accepting new patients. Call (620) 669-2500 or visit HutchClinic.com to schedule a visit.

Ben-Gurion University Researchers Introduce New Method for Diagnosing Neurological and Psychiatric Conditions – PRNewswire

Posted on February 15, 2021 by Danzig

BEER-SHEVA, Israel, Feb. 9, 2021 /PRNewswire/ -- Researchers at Ben-Gurion Universityof the Negev (BGU) have developed a new method for rapidly diagnosing brain blood vessel pathology that may lead to neurodegenerative diseases, such as Alzheimer's disease, as well as other neurological and psychiatric conditions, including epilepsy, traumatic brain injury and stroke. The novel method is based on analysis of EEG patterns using proprietary algorithms and was invented by Dr. Dan Milikovsky and Prof. Alon Friedman, MD-PhD, Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev.

The novel diagnostic method is based on findings from the lab of Prof. Friedman that patients with Alzheimer's disease and other brain conditions display nonconvulsive epileptic seizure-like activity that can be detected by EEG recordings. The study was published in the highly ranked Science Translational Medicine Journal [i]. This abnormal activity reflects pathological changes in dysfunction of the brain blood vessels, which contribute, according to recent studies, to the pathogenesis of various neurodegenerative and other neuro-psychiatric disorders.

"Research from our lab and others, shows that the pathological changes in the brain blood vessels, which are usually referred to as the blood-brain barrier (BBB), contribute to the formation of Alzheimer's disease and other brain disorders. Since dysfunction of the BBB is also a key component in the pathogenesis of epilepsy, we hypothesized that BBB dysfunction in Alzheimer's patients would also trigger abnormal brain activity that could be detected by EEG, an accessible and affordable tool used in the clinic, and serve as a diagnostic method for these conditions," explained Prof. Friedman. "Indeed, we find abnormal, epileptic-like EEG recordings in many patients with Alzheimer's disease as well as epilepsy, which reflect brain blood vessel pathology and can serve both for diagnosis as well as a therapeutic target."

The technology was successfully tested on animal models and dozens of patients and is now been validated on large databases of EEG records of thousands of patients.

"This new approach for diagnosing neurological conditions based on analysis of changes of blood vessels in the brain can be valuable for the early detection of Alzheimer's disease and other neurological conditions, at the stage when treatment can still slow down disease progression. The technology offers a biomarker for immediate results and allows for the continuous monitoring of the progression of the neurological condition and response to treatment," said Josh Peleg, CEO of BGN Technologies. "We are now seeking a potential industry partner for the further development of this promising method for a variety of applications, from monitoring of ICU patients, to patients after stroke and head injuries and for the diagnosis of vascular pathology in early Alzheimer's disease."

About BGN Technologies

BGN Technologiesis the technology transfer companyof Ben-Gurion University, the third largest university in Israel. BGN Technologies brings technological innovations from the lab to the market and fosters research collaborations and entrepreneurship among researchersand students. To date, BGNTechnologieshas established over 100 startup companiesin the fields of biotech, hi-tech, and cleantech, and has initiated leading technology hubs,incubators, and accelerators.Over the past decade, BGN Technologies has focused on creating long-term partnerships with multinational corporations such as Deutsche Telekom, Dell-EMC, PayPal, and Lockheed Martin, securing value and growth for Ben-Gurion University as well as the Negev region.For more information, visit the BGN Technologies website.

[i] Milikovsky1 et al. (Dec. 2019), Paroxysmal slow cortical activity in Alzheimer's disease and epilepsy is associated with blood-brain barrier dysfunction. Science Translational Medicine: Vol. 11, Issue 521, eaaw8954.

Media Contact:Tsipi HaitovskyGlobal Media LiaisonBGN TechnologiesTel: +972-52-598-9892E-mail: [emailprotected]

SOURCE BGN Technologies

See more here:
Ben-Gurion University Researchers Introduce New Method for Diagnosing Neurological and Psychiatric Conditions - PRNewswire

Covid-19 Impact on Neurological Biomarkers Market Size, Share, Trends and Forecast 2021-2026: Abbott, QIAGEN, Thermo Fisher Scientific – KSU | The…

Posted on January 20, 2021 by Danzig

Neurological Biomarkers Market Report recently published by Worldwide Market Reports company focuses mostly on required solutions to the users. The study includes analysis, forecast, and revenue from 2021 to 2026. The advancement rate is evaluated dependent on insightful examination that gives credible information on the worldwide market. Imperatives and advancement points are merged together after a significant comprehension of the improvement of this market.

There is Continuous growth in the Neurological Biomarkers Market in the last five years and also continued for the forecasted period. Neurological Biomarkers industry report analyses the outline of the global market with respect to major regions and segmented by types and applications. This report covers top manufacturers, product scope, market overview, market opportunities, market risk, market driving force, technological advancement, distributors, traders, dealers, research findings.

RequestMore Detailed Information About Industry: Get Sample Report Click Here!

The top players covered in Neurological Biomarkers Market are: Abbott, QIAGEN, Thermo Fisher Scientific, Athena Diagnostics, Bio-Rad Laboratories

The point-to-point elucidation of the markets assembling system, the usage of advancement, conclusions of the world market players, dealers and suppliers order, and the explicit business data and their improvement plans would help our customers for future courses of action and movement planned to make due in the Neurological Biomarkers market.

The data always remains relevant to the market and consists of market dynamics, prospects, starts, market dynamics, and even the Global market volumes into account. It filled with data and deep analysis on market value, environmental analysis, Neurological Biomarkers advanced techniques, latest developments, Neurological Biomarkers business strategies, and current trends. Hence, it becomes a valuable asset to both manufacturers and investors of the industry.

Points Covered of this Neurological Biomarkers Market report are:

The international Neurological Biomarkers market has been characterized by several primary factors, with each factor tends to play a crucial role in the boom of the market. The growth in the products has doubled with the smoother availability of the customer base that has been helping the company flourishing globally. On the other hand, the presence of a dynamic supply chain has helped the company to grow exponentially.

The analysis and forecast of the global market of Neurological Biomarkers have no longer been, specifically, analyzed that are not only on a global foundation but additionally on a neighborhood foundation. When a better look taken at the areas, the market has concentrated, and the file interior the important makes a strong point of Europe, Middle East & Africa, Asia Pacific, Latin America, and North America. These areas have studied regarding the hooked-up traits and the diverse possibilities in addition to the outlook that allows inside the benefitting of the market ultimately.

Request Discount for this Research:(Click Here!)

Research Methodology:

The Neurological Biomarkers market report has been prepared after thorough market research being conducted. It has been prepared as per Porters Five Force Model. In terms of timeline, the market takes the period between 2021-2026 into account for assessment. Apart from this, a comprehensive SWOT analysis has been provided for swift business decision making.

Enumerating some of the fundamental parameters encompassed in the report:

Global Neurological Biomarkers Market Report includes Detailed TOC points:

Customization Service of the Report: (Place Query: Click Here!)

Worldwide Market Reports provides customization of reports as per your request. This report can be personalized to meet your requirements. Get in touch with our research team, who will make sure you get a report that suits your necessities.

Contact Us:Mr. ShahWorldwide Market Reports,Tel: U.S. +1-415-871-0703 / U.K. +44-203-289-4040 / Japan +81-50-5539-1737Email: sales@worldwidemarketreports.com

See the original post:
Covid-19 Impact on Neurological Biomarkers Market Size, Share, Trends and Forecast 2021-2026: Abbott, QIAGEN, Thermo Fisher Scientific - KSU | The...

The Association Between Smoking and Subarachnoid Hemorrhage – Neurology Advisor

Posted on February 2, 2021 by Danzig

Genetically determined smoking behavior is associated with an increased risk for non-traumatic subarachnoid hemorrhage (SAH), according to study results published in Stroke.

Data suggest that smoking is an important risk factor for aneurysm formation and rupture. While previous studies have identified an increased risk for non-traumatic SAH among smokers, the causal association is not well understood. The objective of this study was to determine if smoking is causally related to the risk for SAH.

Study researchers conducted this large prospective study with Mendelian Randomization analyses using data from the UK BioBank, a large cohort study with over 500,000 adults (age, 40-69 years) from 2006 to 2010. Of the 408,609 patients evaluated, 132,566 (32%) ever smoked regularly and 902 (0.22%) were diagnosed with SAH.

A polygenic risk score that represents the genetic propensity to smoke was built using individual-level genetic data and included 126 single nucleotide polymorphisms.

There was a strong association between genetic susceptibility to smoking with both smoking initiation and risk of SAH. Each additional SD of the smoking polygenic risk score was associated with a 21 percent increased risk for smoking initiation (odds ratio [OR], 1.21; 95% CI, 1.20-1.21; P <.001) and with a 10 percent increased risk for SAH (OR, 1.10; 95% CI, 1.03-1.17; P =.006).

In the primary Mendelian Randomization analysis using the ratio method, genetic susceptibility to smoking was linked to a 63 percent increase in risk of SAH (OR, 1.63; 95% CI, 1.15-2.31; P =.006). The results were similar on secondary Mendelian Randomization analyses using the inverse variance weighted method (OR, 1.57; 95% CI, 1.13-2.17; P =.007) and the weighted median method (OR, 1.74; 95% CI, 1.06-2.86; P =.03).

Findings indicated that the genetic susceptibility to smoking initiation was associated with a 60 percent increase in the risk of SAH, and, compared with never smokers, this increased risk was similar for those who smoked 0.05 to 20 packs per year (OR, 1.63; 95% CI, 1.01-2.62; P =.04), 20 to 40 packs per year (OR, 1.65; 95% CI, 1.13-2.41; P =.009) and more than 40 packs per year (OR, 1.56; 95% CI, 1.08-2.25; P =.02).

The study had several limitations, according to the study researchers, including potential misclassification of the outcome secondary to use of ICD codes to determine SAH cases, the absence of an independent dataset to confirm the results, and the limited demographic of the study population (all genetically determined White study participants). As a result, findings cannot be applied to other racial and/or ethnic populations.

We found that a stronger genetic predisposition to smoking is significantly associated with an increased risk of SAH. These findings provide important evidence to support a causal relationship between smoking and the risk of SAH, concluded the study researchers.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Acosta JN, Szejko N, Both CP, et al. Genetically determined smoking behavior and risk of nontraumatic subarachnoid hemorrhage. Stroke. Published online January 14, 2021. doi:10.1161/STROKEAHA.120.031622

More here:
The Association Between Smoking and Subarachnoid Hemorrhage - Neurology Advisor

Long-Term Immunotherapy Linked to Reduced Relapse in Relapsing-Remitting MS – Neurology Advisor

Posted on February 4, 2021 by Danzig

Long-term disease modifying therapies for patients with multiple sclerosis (MS) were effective at reducing relapse and disability accumulation, according to study results published in Neurology.

The predominant goal of MS treatments is the prevention of long-term disability accrual. Study researchers sought to determine whether immunotherapy could prevent long-term disability in patients with relapsing-remitting MS.

In this observational cohort study, researchers assessed patients (N=14,717) with MS who were eligible for class IV immunotherapy. They collected patient data from the MSBase registry.

71% of patients were women (mean age, 36 years; mean age at disease onset, 309 years) and had a median of 6 (interquartile range [IQR], 3.1-10) years of prospective follow-up data. Patients had a median of 4 (IQR, 2-6) relapses, and 69% were exposed to immunotherapies. A total of 1085 patients had at least 15 years of follow-up data (median years of prospective follow-up, 17 years; 95% CI, 15.6-18.8).

Patients who received continuous treatment were less likely to have a relapse event compared with those who were not continuously treated (annual relapse rate, 0.32 vs 0.46, respectively; hazard ratio [HR], 0.60; 95% CI, 0.43-0.82; P =.0016) and less likely to have a 12-month confirmed disability accumulation event (disability accumulation, 0.9 vs 1.5 events, respectively, at 15 years; HR, 0.56; 95% CI, 0.38-0.82; P =.0026).

Compared to untreated patients, fewer patients with continuous treatment reached an Expanded Disability Status Scale (EDSS) step 6 at 15 years (41% vs 13%, respectively; HR, 0.33; 95% CI, 0.19-0.59; P =.00019).

Study researchers did not observe significant difference in disability improvement between the treated and untreated patients (HR, 1.20; 95% CI, 0.96-1.50; P =.1). They also observed similar patterns, stratified by disease duration and age, between these two cohorts.

Limitations of this study include its observational design, the inability to assess delayed treatment effects, and the inability to generalize findings beyond patients with MS followed in academic centers.

These data indicated patients receiving long-term immunotherapy were at decreased risk for disease relapse and neurologic disability escalation. The study authors concluded that sustained, long-term immunotherapy from early stages of MS is advisable as a strategy to preserve patients neurological capacity over the long-term.

Disclosure: Multiple authors declared affiliations with the pharmaceutical industry. Please refer to the original article for a full list of disclosures.

Reference

Kalincik T, Diouf I, Sharmin S, et al. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. Published online December 28, 2020. doi:10.1212/WNL.0000000000011242

The rest is here:
Long-Term Immunotherapy Linked to Reduced Relapse in Relapsing-Remitting MS - Neurology Advisor

Research Antibodies and Reagents Market to Reach $6.32 Billion by 2027 With COVID-19 Impact, at a CAGR of 5.6% from 2020- Meticulous Research Analysis…

Posted on December 1, 2020 by Danzig

London, Dec. 01, 2020 (GLOBE NEWSWIRE) -- In its latest publication, titled Research Antibodies and Reagents Market by Product {Antibodies [Type (Primary, Secondary), Production, Source, Research Area (Oncology, Neurology)], Reagents}, Technology (ELISA, Western Blot), Application, End User (Pharma, Academia) - Global Forecast to 2027, Meticulous Research analyses that the research antibodies and reagents market is expected to grow at a CAGR of 5.6% from 2020 to reach $6.32 billion by 2027.

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5055

Traditionally, antibodies were obtained from blood and serum. However, these antibodies were produced in a limited number and may cause cross-reactivity. This led to an increase in their cost, along with decreasing use in basic research. To overcome these drawbacks and decrease the outgrowth of various diseases, researchers developed different types of antibodies using sophisticated technologies that can produce a large number of antibodies within less time with high specificity and affinity than traditional ones. Thus, to promote research activities, advanced technologies using research antibodies and reagents products are widely used by various end-users.

Factors such as the increasing proteomics and genomics research studies, increased funding for research activities, and growing industry-academia collaborations are majorly driving the research antibodies and reagents market. Also, growing economies, rising protein-based research, and increasing biomarker discovery provide opportunities for the growth of the market. In addition, the growing growing number of research activities due to increasing COVID-19 cases all over the globe is further driving the adoption of research antibodies and reagents by various end-users.

To provide efficient analysis, Meticulous Research has segmented this market by product {antibodies [type (primary antibody, secondary antibody), production type (monoclonal antibody, polyclonal antibody, and antibody fragments), source (mouse, rabbit, and others), research area (oncology, cardiovascular disease, infectious diseases, immunology, neurology, stem cell research, and others)], reagents [sample preparation reagents (media and serum, stain and dyes, probes, buffers, and solvents), antibody production reagents (enzymes and proteins), other research reagents}, technology (western blot, immunofluorescence, ELISA, multiplex immunosorbent assay, flow cytometry, immunohistochemistry, immunoprecipitation, and others), application (proteomics, drug discovery and development, and genomics), end user (pharmaceutical and biotechnology industry, academic and research institutes, and contract research organizations), and geography (Asia-Pacific, Europe, North America, the Middle East & Africa, and Latin America).

Wish to customize this report or get any additional specific information of your interest? Let us know here-https://www.meticulousresearch.com/custom-research.php

In 2020, geographically, North America is projected to command the largest share of the research antibodies and reagents market, closely followed by Europe and Asia-Pacific. However, Asia-Pacific region is expected to grow at the fastest rate due to growing R&D investment in proteomics research, rising middle-income people, growing focus on the pharma sector, and improving healthcare industry.

Based on product, the reagents segment is projected to grow at the fastest growth rate of the overall research antibodies and reagents market due to increasing focus on understanding the molecular basis of diseases and routine use in target-based assays during the basic research and huge demand for various reagents in many routine assays.

In 2020, the flow cytometry segment is expected to command the largest share of the overall research antibodies and reagents market. Growing focus on biomedical research for improving diagnosis and therapy developments and growing focus on biomarker discovery and cell-based research are the key factors driving the growth of this segment.

In 2020, on the basis of application, the proteomics segment is poised to command the largest share of the overall research antibodies and reagents market. The upsurge in proteomics research is attributed to the rising need to design more effective drugs through protein-based disease profiling, rising uptake of research antibodies in the significantly growing proteomics market, and increasing public & private sector spending on proteomic research.

Quick Buy -Research Antibodies And Reagents Market Research Report:https://www.meticulousresearch.com/buy_now.php?pformat=356&vformat=1055

On the basis of end user, in 2020, the pharmaceutical and biotechnology industry segment is estimated to command the largest share of the research antibodies and reagents market due to the highest adoption of antibodies and reagents by this end-user for increasing research activities.

The report includes a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by leading market players in the industry over the past four years (2016-2019). The key players profiled in the research antibodies and reagents market are GE Healthcare (U.S.), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann La-Roche AG (Switzerland), Rockland Immunochemicals Inc. (U.S.), Johnson & Johnson (U.S.), Agilent Technologies, Inc. (U.S.), Eli Lily and Company (U.S.), Becton Dickinson and Company (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), GenScript Biotech Corporation (U.S.), Lonza (Switzerland), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Santa Cruz Biotechnology, Inc. (U.S.), and BioLegend, Inc. (U.S.) among others.

To gain more insights into the market with a detailed table of content and figures, click here:https://www.meticulousresearch.com/product/research-antibodies-reagents-market-5055/

Scope of the Report:

Research Antibodies And Reagents Market, by Product Type

Research Antibodies And Reagents Market, by Technology

Research Antibodies And Reagents Market, by Application

Research Antibodies And Reagents Market, by End User

Research Antibodies And Reagents Market, by Geography

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5055

Amidst this crisis, Meticulous Researchis continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here-https://www.meticulousresearch.com/custom-research.php

Related Reports:

Contract Research Organizations (CRO) Market by Services (Clinical Research [Phase II, Phase III], Pre-Clinical [Pharmacokinetics, Toxicology], Laboratory Services, and others), Therapeutic Area (Oncology, Immunology), End User (Pharma and Biotech, Medical Device), and Geography - Forecast to 2027

https://www.meticulousresearch.com/product/CRO-market-5129/

In Vitro Diagnostic (IVD) Reagents Market by Type (Antibodies, Oligonucleotide, Nucleic Acid Probe), Technology (Immunoassay, Hematology, Microbiology), Use (Research, Analyte Specific Reagent), End User (IVD Manufacturer, Clinical Laboratory) Global Forecast to 2027

https://www.meticulousresearch.com/product/in-vitro-diagnostic-reagents-market-5110/

Infectious Disease Diagnostics Market by Product and Solution (Consumables, System, Software and Services), Technology (Immunodiagnostics, PCR, INAAT), Disease (HIV, HAIS, Influenza), End User (Hospital, Reference Lab, Research) - Global Forecast to 2027

https://www.meticulousresearch.com/product/infectious-disease-diagnostics-market-4976/

COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025

https://www.meticulousresearch.com/product/COVID-19-impact-assessment-health-and-life-sciences-industry-5098/

About Meticulous Research

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:Mr. Khushal BombeMeticulous ResearchDirect Lines: +1-646-781-8004 (North America)+44-203-868-8738 (Europe)+91 744-7780008 (Asia-Pacific)Email-sales@meticulousresearch.comVisit Our Website:https://www.meticulousresearch.com/Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-researchContent Source:https://www.meticulousresearch.com/press-release/research-antibodies-reagents-market-2027/514

Excerpt from:
Research Antibodies and Reagents Market to Reach $6.32 Billion by 2027 With COVID-19 Impact, at a CAGR of 5.6% from 2020- Meticulous Research Analysis...

Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND – GlobeNewswire

Posted on December 4, 2020 by Danzig

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/MND taking place online from December 9 December 11, 2020.

Title: A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS): COURAGE-ALS Trial DesignSession: Live Poster Session ADate: December 9, 2020Theme: 09 Clinical Trials and Trial DesignPresentation Time: 5:10 5:50 PM GMTPoster Number: CLT-04Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology atBarrow Neurological Institute, and Professor and Executive Chair of Neurology at theUniversity of Arizona,Phoenix

Title: Impact of Patient Characteristics on Effect Size in FORTITUDE-ALSSession: Live Poster Session BDate: December 10, 2020Theme: 09 Clinical Trials and Trial DesignPresentation Time: 5:10 5:50 PM GMTPoster Number: CLT-17Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology atBarrow Neurological Institute, and Professor and Executive Chair of Neurology at theUniversity of Arizona,Phoenix

Title: People Living with ALS and Their Caregivers Input into Drug Development in EuropeSession: Live Poster Session CTheme: 13 Clinical Management, Support and InformationDate: December 11, 2020Presentation Time: 12:05 12:50 PM GMTPoster Number: CMS-33Poster Presenter: Miriam Galvin, Ph.D., Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing for regulatory interactions for omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing CK-274, a next- generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is considering potential advancement of reldesemtiv to Phase 3 pending ongoing regulatory interactions. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information aboutCytokinetics, visitwww.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential benefits of reldesemtiv, including its ability to represent an additive and complementary approach to increase muscle function; Cytokinetics and its partners research and development activities; the timing of enrollment of patients in Cytokinetics and its partners clinical trials; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; Cytokinetics drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics or its partners ability to conduct clinical trials; and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas decisions with respect to the design, initiation, conduct, timing and continuation of development activities for reldesemtiv; standards of care may change, rendering Cytokinetics drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission.

Contact:CytokineticsDiane WeiserSenior Vice President, Corporate Communications, Investor Relations(415) 290-7757

Sustained Benefit of Ocrelizumab Treatment for Primary Progressive MS – Neurology Advisor

Posted on November 20, 2020 by Danzig

Long-term follow-up from the phase 3 ORATORIO extension study (ClinicalTrials.gov Identifier: NCT01194570) provided evidence of a consistent, long-term benefit of early and continuous ocrelizumab treatment on disease progression in primary progressive multiple sclerosis (PPMS), according to study results published in the Lancet Neurology.

Data from the phase 3 ORATORIO trial supported the safety and efficacy of ocrelizumab for patients with PPMS. The objective of this follow-up study was to evaluate the long-term safety and efficacy of maintaining or switching to ocrelizumab therapy in the open-label extension phase of the trial.

ORATORIO was a multi-center, double-blind, phase 3 trial of 732 patients with PPMS. Patients were aged 18-55 years and randomly assigned to receive intravenous ocrelizumab or placebo, every 24 weeks for at least 120 weeks. After the double-blind phase, the participants entered an extended controlled period, followed by an open-label extension phase, during which they continued ocrelizumab or switched from placebo to ocrelizumab.

Time to onset of disability progression was confirmed at 24 weeks months by using 4 measures: increase in Expanded Disability Status Scale score; 20% or more increase in time to complete the 9-Hole Peg Test; 20% or more increase in time to perform the Timed 25-Foot Walk; and composite progression, defined as the first confirmed occurrence of any of these three individual measures.

Of 732 participants, 544 (74%) completed the double-blind period to week 144; 517 of these patients and 10 additional ones (total, 527 [72%]) entered the open-label extension phase. Of the 527 patients, 451 (86%), were ongoing in the open-label extension.

Over a period of 6.5 study years, there was a consistent and sustained treatment-associated benefit in multiple measures of disability progression. The proportion of patients with worsening disability measures was lower in those who initiated ocrelizumab early, compared with those who switched from receiving placebo: Expanded Disability Status Scale (51.7% vs 64.8%, respectively; P =.0018); 9-Hole Peg Test (30.6% vs 43.1%, respectively; P =.0035); Timed 25-Foot Walk (63.2% vs 70.7%, respectively; P =.058), and composite progression (73.2% vs 83.3%, respectively; P =.0023).

Percent changes in T2 lesion volume (0.447% vs 13.002%, respectively; P <.0001) and T1 hypointense lesion volume (36.676% vs 60.925%, respectively; P =.0008) from baseline to the end of the study were lower for patients who were on ocrelizumab from the double-blind phase of the study, compared with those who switched from placebo.

The rate of adverse events and serious adverse events over the entire period in the all-ocrelizumab exposure population were 238.09 (95% CI, 232.71-243.57) per 100 patient-years and 12.63 (95% CI, 11.41-13.94) per 100-patient years, respectively. The most common serious adverse events were serious infections with a rate of 4.13 (95% CI, 3.45-4.91) per 100 patient-years. No new safety signals emerged.

The study had several limitations, including the lack of a control group, open-label treatment, and potential survivor bias.

Although this study shows the benefit of earlier intervention with ocrelizumab in primary progressive disease, progression remains an important unmet need in multiple sclerosis, concluded the study researchers.

Reference

Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. Published online October 29, 2020). doi:10.1016/S1474-4422(20)30342-2

Follow this link:
Sustained Benefit of Ocrelizumab Treatment for Primary Progressive MS - Neurology Advisor

Select Page ::